甘李药业(603087) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 reached CNY 984.87 million, a 75.76% increase compared to CNY 560.33 million in the same period last year[5]. - Net profit attributable to shareholders was CNY 311.92 million, reflecting a significant increase of 224.90% from CNY 96.00 million year-on-year[5]. - The net profit excluding non-recurring gains and losses was CNY 214.65 million, up 1,150.17% from CNY 17.17 million in the previous year[5]. - Basic earnings per share rose to CNY 0.53, representing a 231.25% increase from CNY 0.16 year-on-year[5]. - Total operating revenue for Q1 2025 reached ¥984.87 million, a significant increase of 75.7% compared to ¥560.33 million in Q1 2024[21]. - Net profit for Q1 2025 was ¥311.92 million, up 225.5% from ¥96.00 million in Q1 2024[21]. - Basic and diluted earnings per share for Q1 2025 were both ¥0.53, compared to ¥0.16 in Q1 2024[22]. - The company reported a total profit of ¥360.39 million for Q1 2025, compared to ¥113.56 million in Q1 2024, reflecting a growth of 217.5%[21]. - The company’s total comprehensive income for Q1 2025 was ¥312.26 million, compared to ¥95.89 million in Q1 2024, marking a growth of 226.5%[21]. Cash Flow and Assets - Cash flow from operating activities was CNY 158.75 million, a 95.29% increase compared to CNY 81.29 million in the same period last year[5]. - Cash flow from operating activities for Q1 2025 was ¥158.75 million, an increase of 95.5% from ¥81.29 million in Q1 2024[23]. - The company's total assets increased by 2.01% to CNY 12.28 billion compared to the end of the previous year[5]. - The company's total assets as of March 31, 2025, amount to ¥12,284,434,818.79, an increase from ¥12,042,916,391.88 at the end of 2024[18][19]. - Current assets total ¥3,900,272,940.75, showing an increase from ¥3,790,858,209.05[18]. - The company's cash and cash equivalents stand at ¥1,058,837,161.68, up from ¥902,777,760.68[18]. - Cash and cash equivalents at the end of Q1 2025 totaled ¥372.30 million, up from ¥337.92 million at the end of Q1 2024[23]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 74,987[15]. - The largest shareholder, Gan Zhongru, holds 205,643,757 shares, accounting for 34.21% of total shares[15]. - The company has pledged 28,210,000 shares held by Gan Zhongru[15]. - The equity attributable to shareholders of the parent company is ¥11,312,123,449.60, compared to ¥11,054,470,662.18 previously[19]. - The company has no significant changes in shareholder relationships or actions during the reporting period[17]. Sales Performance - Domestic sales revenue was CNY 889 million, up 80.07% from the previous year, driven by significant growth in insulin product sales[12]. - International sales revenue reached CNY 95 million, a 45.21% increase compared to the same period last year, supported by expanding international market efforts[14]. Operating Costs and Expenses - Total operating costs for Q1 2025 were ¥739.37 million, an increase of 36.4% from ¥541.95 million in Q1 2024[21]. - Research and development expenses for Q1 2025 were ¥130.45 million, slightly down from ¥133.12 million in Q1 2024[21]. Future Plans - The company plans to continue deepening its global layout and drive export business growth through innovation[14]. Inventory and Liabilities - The company reported an increase in inventory to ¥1,113,062,811.37 from ¥1,052,906,832.75[18]. - Total liabilities decreased to ¥972,311,369.19 from ¥988,445,729.70[19].